{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-095931","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2026-08-13T20:15:21+00:00","discovered_at":"2026-08-13T20:17:00.366531+00:00","generated_at":"2026-08-13T20:17:56.405334+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fortress Biotech Q2 2026 revenue up 14% to $18.7M; net loss $2.5M vs prior-year income","bullets":["Q2 2026 net revenue $18.7M (up 14% YoY from $16.4M); net loss attributable to common stockholders $(2.5)M ($0.08/share) vs net income $13.4M ($0.50/share) in Q2 2025.","Cash and equivalents $196.6M at June 30, 2026, up from $79.4M at Dec 31, 2025, boosted by $205M PRV sale from ZYCUBO.","Crystalys closed $130M Series B financing for dotinurad; Urica holds equity and 3% royalty on future net sales.","Journey Medical expanded Emrosi payer access to over 150M commercial lives (~85% of US commercial lives); Q2 net product revenue $17.8M vs $15.0M YoY.","AstraZeneca reported anselamimab subgroup analysis: 62% survival improvement and 71% reduction in cardiovascular hospitalizations in kappa AL amyloidosis; regulatory submission planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-095931","json":"https://secwatch.observer/filing/0001104659-26-095931.json","markdown":"https://secwatch.observer/filing/0001104659-26-095931.md","text":"https://secwatch.observer/filing/0001104659-26-095931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/0001104659-26-095931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/fbio-20260813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:17:56.405334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}